Výsledky vyhledávání

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

P579 Real-world comparison of effectiveness between tofacitinib and ustekinumab in patients with ulcerative colitis exposed to at least one anti-TNF agent: results from the TORUS study

Autor: A Buisson, M Serrero, R Altwegg, T Guilmoteau, G Bouguen, M Nachury, A Amiot, L Vuitton, X Treton, L Caillo, B Pereira, M Fumery

Publikováno v: Journal of Crohn's and Colitis
Journal of Crohn's and Colitis, 2023, 17 (Supplement_1), pp.i707-i707. ⟨10.1093/ecco-jcc/jjac190.0709⟩

Background We aimed to compare the effectiveness of tofacitinib and ustekinumab in patients with ulcerative colitis (UC) previously exposed to at least one anti-TNF agent. Methods In this multicenter study, we retrospectively included consecutive UC

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cffb7d754eb5a4a75892bacb4ceef6c4
https://u-picardie.hal.science/hal-04161046

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Comparative Risk of Incident Cancer in Patients with Inflammatory Bowel Disease with Prior Non-digestive Malignancy According to Immunomodulator: a Multicentre Cohort Study

Publikováno v: Journal of Crohn's and Colitis
Journal of Crohn's and Colitis, 2022, 16 (10), pp.1523-1530. ⟨10.1093/ecco-jcc/jjac061⟩

Introduction Knowledge about the cancer risk when initiating a biologic in inflammatory bowel disease [IBD] patients with prior malignancy remains scarce, especially for vedolizumab. Our aim was to evaluate the rate of incident cancer in a cohort of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17f22cc6a4e0b0eee459214fd8327e50
https://pubmed.ncbi.nlm.nih.gov/35512337

Zobrazit plný text záznamu

P142 Inflammatory bowel diseases associated with primary immunodeficiency: a multicenter study

Autor: G Malamut, M Simon, M Nachury, M Uzzan, M Serrero, M Fumery, C Trang-Poisson, C Zallot, V Abitbol, F Charbit-Henrion, J M Gornet, C Picard, N Cerf-Bensussan, S Chaussade, H Sokol

Publikováno v: Journal of Crohn's and Colitis. 16:i223-i224

Background Inflammatory bowel diseases (IBD) associated with primary immunodeficiency (PID) remain poorly known. We aimed to isolate characteristics of IBD associated with PID. Methods Using a GETAID register, we reviewed medical files of recorded pa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::511915a118676c49454232ab1166564f
https://doi.org/10.1093/ecco-jcc/jjab232.270

Zobrazit plný text záznamu

P350 Comparative risk of incident cancer in patients with Inflammatory Bowel Disease with prior non-digestive malignancy according to immunomodulator: a multicenter cohort study

Publikováno v: Journal of Crohn's and Colitis. 16:i362-i363

Background Knowledge about the cancer risk when initiating a biologic in Inflammatory Bowel Disease (IBD) patients with prior malignancy remains scarce especially for vedolizumab. Our aim was to evaluate the rate of incident cancer in a cohort of IBD

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::47bf39e32332b9d906e104e83d7416d9
https://doi.org/10.1093/ecco-jcc/jjab232.477

Zobrazit plný text záznamu

P140 Immunomodulators are protective against severe COVID 19: results from a large multicentre cohort of inflammatory bowel disease patients

Publikováno v: Journal of Crohn's and Colitis. 16:i222-i223

Background In the context of the Sars-Cov2 pandemic, the management of patients with chronic diseases and/or receiving immunosuppressive drugs was of concern due to lack of data to dictate their management. The objectives of our study were to evaluat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::509fc584ab3b22bd05c618199520e5ce
https://doi.org/10.1093/ecco-jcc/jjab232.268

Zobrazit plný text záznamu

DOP36 Efficacy and safety of vedolizumab in patients with chronic active pouchitis refractory to anti-TNF therapy: Results of a retrospective multicenter study

Autor: M Sallette, Y Bouhnik, M Nachury, C Bellanger, D Laharie, A Amiot, L Peyrin-Biroulet, X Roblin, R Altwegg, A Buisson, C Reenaers, G Bouguen, L Vuitton, A Bourreille, C Gilletta, M Serrero, X Hébuterne, J Filippi

Publikováno v: Journal of Crohn's and Colitis. 16:i084-i085

Background Total coloproctectomy with ileoanal anastomosis (IAA) is the procedure of choice for patients with treatment-resistant ulcerative colitis (UC). It is most often curative, but can be complicated by pouchitis in 30% of cases, which becomes c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::739db2f79fbf5b519c8a25d54ed5cec6
https://doi.org/10.1093/ecco-jcc/jjab232.075

Zobrazit plný text záznamu

P604 Infection Risk in Elderly Patients with Inflammatory Bowel Disease under anti-TNF, ustekinumab or vedolizumab biologic therapies: A Prospective Multicenter observational One-Year follow-up comparative study

Autor: A Bozon, M Serrero, L Caillo, C Gilletta, A Benezech, S Nancey, R Combes, G Danan, S Akouete, L Pages, J F Bourgaux, L Boivineau, M Meszaros, R Altwegg

Publikováno v: Journal of Crohn's and Colitis. 16:i537-i537

Background The emergence of biologics has significantly improved the course of inflammatory bowel diseases (IBD) despite a potential higher risk of infections. Use of biologics in the elderly population remains a challenge since elderly patients are

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a1cfeeae58ed6eb48d89f6c661c643dd
https://doi.org/10.1093/ecco-jcc/jjab232.730

Zobrazit plný text záznamu

DOP76 Real-world multicenter comparison of effectiveness between tofacitinib and vedolizumab in patients with Ulcerative Colitis after failure to at least one anti-TNF agent

Autor: A Buisson, M Nachury, M Fumery, T Guilmoteau, E Leclerc, R Altwegg, M Serrero, N Mathieu, X Treton, L Vuitton, B Pereira, A Amiot, G Bouguen

Publikováno v: Journal of Crohn's and Colitis. 16:i120-i120

Background Several therapeutic options are now available in ulcerative colitis after anti-TNF failure, but no data compared hitherto tofacitinib and vedolizumab. We compared the effectiveness of tofacitinib and vedolizumab in UC patients with prior e

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::153752cd45e6980c78f8a4c8482fd347
https://doi.org/10.1093/ecco-jcc/jjab232.115

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání